Microlytic Gets $3.5M VC Investment | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Microlytic, a Copenhagen, Denmark-based protein crystallization tools firm, announced today that it has raised $3.5 million in venture capital funding.

The firm, which also has operations in Boston, plans to use the funds to expand sales and production of products for the structural biology market. It makes the Crystal Former device for crystallizing proteins and MCSG Screens, a set of crystallization reagents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.